CytRx Corp (CYTR) Posts Surprise Q1 Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aegis Capital Keeps CytRx (CYTR) at Buy following Updated Aldoxorubicin Phase 1b/2 Data
May 5, 2014 11:54 AM EDTAegis Capital reiterates its Buy rating and $12 price target on CytRx Corp. (Nasdaq: CYTR) following the presentation of updated progression-free survival (PFS) and overall survival (OS) results from its completed Phase 1b/2 trial of aldoxorubicin in patients with advanced soft tissue sarcoma... More
